Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

357
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
357
Allergic Drug Reactions01:27

Allergic Drug Reactions

876
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
876
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Allergic Reactions02:06

Allergic Reactions

27.8K
Overview
27.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Molecular Traces of Gastric Cancer in Saliva: From Tissue Signatures to Salivary SLC5A5 as a Potential Biomarker.

United European gastroenterology journal·2026
Same author

Malignant Small Bowel Neoplasms: A 20-Year Retrospective Analysis in a Tertiary Center.

GE Portuguese journal of gastroenterology·2026
Same author

Wearable Health Systems.

Studies in health technology and informatics·2026
Same author

Assessing Inflammatory Bowel Disease Care Quality in Portugal: A Nationwide Gastroenterologist Survey.

GE Portuguese journal of gastroenterology·2026
Same author

The modified Baveno classification for obstructive sleep apnoea: design of a pan-European prospective study.

Sleep medicine·2026
Same author

Considerations in planning a controlled human infection model in at-risk groups in sub-Saharan Africa: the case for pneumococcal challenge in people living with HIV in Malawi and a report of stakeholder consultation.

Wellcome open research·2025

相关实验视频

Updated: Jul 20, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804

托法西提尼布诱导的埃索诺菲利亚

Sara Archer1, Daniela Ferreira2, Ana Teresa Ferreira2

  • 1Gastroenterology, Centro Hospitalar Universitário de Santo António, Portugal.

Revista espanola de enfermedades digestivas
|August 4, 2023
PubMed
概括

托法西提尼布是治疗性结肠炎 (UC) 的JAK抑制剂,很少会导致乙氨基和急性损伤. 这一案例突出了潜在的不良影响,强调了在UC治疗期间仔细监测患者.

更多相关视频

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.6K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

相关实验视频

Last Updated: Jul 20, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.6K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

科学领域:

  • 胃肠病学和肝病学 胃肠学和肝病学
  • 药理学和治疗学 药理学和治疗学
  • 临床病例报告 临床病例报告

背景情况:

  • 托法西提尼布是一种经批准的口服JAK抑制剂,用于中度至严重的性结肠炎 (UC).
  • 它的有效性和安全性是在临床试验和现实世界的数据中确立的.
  • 这份报告详细介绍了一名耐火左侧UC患者,此前曾接受过infliximab,vedolizumab和tacrolimus治疗.

研究的目的:

  • 报告患有性结肠炎的患者对托法西提尼布的罕见不良反应.
  • 描述托法西提尼布诱导的黄和急性损伤的临床表现,管理和解决方案.
  • 强调监测JAK抑制剂不常见的不良反应的重要性.

主要方法:

  • 一个18岁的女性患者的病例报告,患有耐火左侧性结肠炎.
  • 由于先前的皮质类固醇不耐受性而启动托法西提尼布.
  • 在托法西提尼布治疗期间监测临床症状,实验室参数 (包括乙氨基酸细胞计数) 和功能.

主要成果:

  • 开始托法西提尼布治疗没有导致UC初始改善,随后出现了持续的外围好色素和急性损伤.
  • 暂时和随后的永久性暂停托法西提尼布导致埃索诺菲利亚的解决和功能正常化.
  • 患者通过替代疗法 (皮质类固醇,乌斯特基努马布,塔克罗利斯) 实现了临床缓解.

结论:

  • 托法西提尼布可能与罕见的不良反应有关,如埃索诺菲利亚和急性损伤,即使在患有UC的患者中.
  • 这一病例代表了在性结肠炎的背景下首次报告的托法西提尼布诱导的埃索诺菲利亚病例.
  • 对不常见的不良事件的警和及时识别对于在JAK抑制剂治疗期间的患者安全至关重要.